Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;12(2):147-56.
doi: 10.1002/mrdd.20105.

Childhood multiple sclerosis: a review

Affiliations
Review

Childhood multiple sclerosis: a review

Amy Waldman et al. Ment Retard Dev Disabil Res Rev. 2006.

Abstract

Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS) that is increasingly recognized as a disease that affects children. Similar to adult-onset MS, children present with visual and sensory complaints, as well as weakness, spasticity, and ataxia. A lumbar puncture can be helpful in diagnosing MS when CSF immunoglobulins and oligoclonal bands are present. White matter demyelinating lesions on MRI are required for the diagnosis; however, children typically have fewer lesions than adults. Many criteria have been proposed to diagnose MS that have been applied to children, mostly above 10 years of age. The recent revisions to the McDonald criteria allow for earlier diagnosis, such as after a clinically isolated event. However, children are more likely than adults to have monosymptomatic illnesses. None of the approved disease-modifying therapies used in adult-onset MS have been approved for pediatrics; however, a few studies have verified their safety and tolerability in children. Although children and adults with MS have similar neurological symptoms, laboratory (cerebrospinal fluid) data, and neuroimaging findings, the clinical course, pathogenesis, and treatment of childhood onset MS require further investigation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aharoni R, Kayhan B, Eilam R, et al. 2003. Glatiramer acetate‐specific T cells in the brain express T helper 2/3 cytokines and brain‐derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100: 14157–14162. - PMC - PubMed
    1. Azoulay D, Vachapova V, Shihman B, et al. 2005. Lower brain‐derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 167: 215–218. - PubMed
    1. Banwell B, Reder AT, Krupp L, et al. 2006. Safety and tolerability of interferon β‐1b in pediatric multiple sclerosis. Neurology 66: 472–476. - PubMed
    1. Barkhof F, Filippi M, Miller DH, et al. 1997. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120: 2059–2069. - PubMed
    1. Barkhof F, Hommes O, Scheltens P, et al. 1991. Quantitative MRI changes in gadolinium‐DTPA enhancement after high‐dose intravenous methylprednisolone in multiple sclerosis. Neurology 41: 1219–1222. - PubMed

Substances